Study guide

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

Key Takeaways Explain This Topic AI

Most CGC stems are multi-domain vignettes: intake and phenotype (D1) feed risk math (D2), test choice and interpretation (D3), counseling moves (D4), and finance/legal/resource steps (D5) in one clinical arc.

Work cases in sequence—clarify indication → quantify risk → choose modality → interpret with residual risk → counsel and document → address coverage, GINA/HIPAA, and resources—then pick the single best next step the stem asks for.

ABGC’s scored mix is D1=34, D2=32, D3=35, D4=30, D5=39; study time should track those weights, with Domain 5 never treated as optional soft content.

Expect Application/Analysis on 75–80% of items; pretest items are indistinguishable, so pace all 200 questions across 4 hours (~1.2 minutes each) without hunting for unscored questions.

Cross-domain traps include equating NIPT with diagnosis, overcalling VUS as pathogenic, guaranteeing insurance or GINA protections beyond statute, and choosing a supportive counseling line that skips informed consent or documentation duties.

Last updated: August 2026

Why integration is the real exam skill

Chapters 1–19 taught Domains 1–5 as separable competencies. On the ABGC Certified Genetic Counselor (CGC®) exam, most stems are not pure domain drills. A prenatal NIPT result, an oncology VUS, or a denied panel usually requires you to thread clinical intake, risk assessment, testing strategy, counseling process, and finance/legal judgment—then answer the narrow question asked (best next step, risk statement, counseling response, or advocacy action).

Official logistics: 200 items ( 170 scored + 30 pretest ), 4 hours , Prometric center or remote. Cognitive mix is Recall 20–25% and Application/Analysis 75–80% . Pretest items are invisible. Scored weights: D1=34, D2=32, D3=35, D4=30, D5=39 . Integration practice converts siloed knowledge into the application behavior ABGC scores.

A working sequence for multi-domain stems

Use this checklist on every long vignette. Distractors usually break one link in the chain.

  • Step Domain lens What you extract from the stem
  • 1. Indication & phenotype D1 Why referred? History, developmental clues, cancer ages/pathology, urgency
  • 2. Pedigree & risk D2 Inheritance model, Mendelian/Bayesian prior, residual risk after negatives
  • 3. Test choice D3 Screening vs diagnostic, sample/method fit, gestational or treatment timing
  • 4. Interpretation D3 P/LP/VUS/negative; mosaicism; discordance; cascade implications
  • 5. Counsel & educate D4 Agenda, psychosocial response, non-directive framing, teach-back, documentation
  • 6. Finance / legal / resources D5 PA/LMN, GINA/HIPAA limits, resource referral, scope and integrity

Exam cue: When an option mixes a correct scientific fact with a wrong process step (or vice versa), choose what is clinically accurate and procedurally appropriate for the asked task .

Worked case A — Prenatal NIPT+ and CVS mosaicism

Stem skeleton: A 34-year-old at 12 weeks has NIPT positive for trisomy 21 . She wants “confirmation as soon as possible.” CVS returns mosaic trisomy 21 . She asks whether the baby “definitely has Down syndrome,” whether she should terminate today, and whether her employer will “find out and fire her.” Insurance has not authorized amniocentesis.

Domain 1. Confirm gestational age, ultrasounds, pregnancy history, and that NIPT is screening . Immediate tasks: separate screen-positive from diagnostic status and explain mosaic CVS (true fetal mosaicism vs confined placental mosaicism).

Domain 2. Post-CVS mosaic result is not “100% affected.” Residual uncertainty may remain until amniocentesis or postnatal studies—boards punish absolute language after mosaic CVS alone.

Domain 3. After high-risk NIPT, pursue diagnostic testing (CVS or amniocentesis), not repeat NIPT. After mosaic CVS, next steps often include amniocentesis and/or detailed ultrasound to evaluate CPM versus true fetal involvement—state timing and procedure risks honestly.

Domain 4. Non-directive exploration of values and timing; plain-language mosaicism teaching with teach-back. Address fear without soft-pedaling uncertainty or steering the pregnancy decision.

Domain 5. GINA limits certain health-insurer and employer uses of genetic information but has scope limits (life/disability/long-term care often outside). Do not promise “your employer can never find out.” Verify PA for diagnostic testing; if delay threatens options, discuss urgency, LMN/appeal, and self-pay without guaranteeing coverage .

Best-next-step pattern: For result counseling, prefer accurate uncertainty + diagnostic follow-up over “this confirms Down syndrome.” For clinical action, prefer diagnostic clarification over repeating NIPT. For employment fear, prefer accurate GINA/HIPAA-scope counseling over absolute reassurance.

Worked case B — Oncology BRCA VUS with GINA/insurance counseling

Stem skeleton: A 42-year-old with breast cancer at 41 and a mother with ovarian cancer at 55 completes a hereditary cancer panel: BRCA2 VUS . She asks about risk-reducing oophorectomy “because of the BRCA result,” relative testing for the VUS, and hiding the result from her employer-sponsored health plan so premiums do not rise. PA was already approved.

Domain 1–2. History met testing criteria; elevated familial prior remains relevant, but a VUS is not pathogenic for Mendelian counseling. Relative testing of a VUS is generally not used for predictive cascade surgery decisions the way a known P/LP variant is.

Domain 3. Do not convert VUS into a positive BRCA diagnosis. Base surgery/surveillance primarily on personal/family history and guidelines ; discuss possible reclassification. Distractors: random broader sequencing without indication, or “ignore family history because no P/LP was found.”

Domain 4. Address urgency without false certainty; explore surgical motivations; document that VUS limitations were explained.

Domain 5. Counsel GINA accurately for health insurance/employment contexts and its limits. Hiding results or falsifying history is unethical. The live conflict is misusing a VUS for irreversible decisions and overclaiming legal protection —not PA (already approved).

Boards favor answers that refuse to manage VUS as pathogenic, avoid routine relative VUS testing for predictive surgery, keep GINA claims inside statute, and center decisions on cancer history plus evidence-based risk management.

Cross-domain trap patterns

  • Trap pattern Domains mixed Why it fails
  • Treating NIPT+/screen as diagnostic D1/D3/D4 Screening ≠ diagnostic confirmation
  • Absolute fetal diagnosis from mosaic CVS alone D2/D3 CPM vs true mosaicism unresolved
  • Managing VUS like P/LP D3/D4 Wrong surgical/cascade counseling
  • “Guidelines guarantee insurance” D3/D5 Medical necessity ≠ automatic payment
  • Overbroad GINA promises D4/D5 Statute scope limits; life/disability often outside
  • Empathy without informed content D4 Warmth ≠ adequate consent/education
  • Perfect science, wrong next step All Stem asked process/advocacy, not a definition
  • Ignoring Domain 5 in “clinical” stems D5 Largest scored block (39); often embedded
  • Study tactics mapped to scored weights
  • Domain Scored items Study implication
  • D1 34 Intake + condition recognition/urgency—not encyclopedic rare-disease lists
  • D2 32 Daily pedigree + Mendelian/Bayesian drills; residual risk after negatives
  • D3 35 Method choice; P/LP/VUS language; prenatal screen vs diagnostic pathways
  • D4 30 Choose among plausible counseling lines; psychosocial + education + documentation
  • D5 39 PA/LMN, resources, GINA/HIPAA, ethics/scope—highest raw count; not optional

Application-first prep: For each major topic, write one vignette that forces a next step . Mirror the 75–80% application mix in practice. A 10% Domain 5 deficit costs more scored items than the same deficit in Domain 4.

Test-day pacing and pretest discipline

Budget: 240 minutes ÷ 200 items ≈ 1.2 minutes/item . Flag and move; return if time remains.

Pretest (30): Invisible—never hunt for them.

Charge line: Re-read “best next step / most accurate statement / most appropriate counseling response?” before choosing.

Eliminate options that are factually true but answer a different domain than asked.

Absolute language (“always,” “confirms,” “guarantees coverage/protection”) is a frequent wrong-answer marker.

Endgame: Clear flagged items in the last 20–30 minutes; educated guess rather than blank if required.

Capstone checklist

Narrate Cases A and B domain-by-domain without notes.

Recall D1–D5 scored counts and the 170/30 split.

Pace full-length sets at ~1.2 min/item.

Label wrong answers by the broken domain link (risk vs interpret vs counsel vs legal).

Integration is the exam’s operating system: keep the clinical arc intact under time pressure, and siloed facts become usable board answers.